4.6 Review

IgG4-related disease: A relatively new concept for clinicians

Journal

EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 27, Issue -, Pages 1-9

Publisher

ELSEVIER
DOI: 10.1016/j.ejim.2015.09.022

Keywords

IgG4-related disease; IgG4 immunoglobulin; Diagnosis; Treatment

Funding

  1. Agnes&Mac Rudbergs foundation
  2. Gustav Prims Reumatikerfond foundation

Ask authors/readers for more resources

IgG4-related disease (IgG4-RD) is a recently recognized chronic fibrotic inflammation, which can affect almost every organ, and may conic to clinical attention first due to visible organ swelling or organ dysfunction, or is identified incidentally by imaging and specific biopsy. The disorder has an allergic background and is immune mediated. Up -regulated responses of T helper 2 and T regulatory cells and their cytokines play a major role in disease progression. About 30-50% of patients are atopic or have mild eosinophilia. IgG4-RD predominantly affects middle-aged male patients. The cornerstones of diagnosis of the disease are compatible clinical features and typical histopatholog,y. Swelling of salivary and lacrimal glands, lymphadenopathy, and type 1 autoimmune pancreatitis (ALP) are the most common manifestations of the disease. However, other tissues and organs, such as retroperitoneum, lung, kidney, aorta, upper airways, thyroid gland, meninges, heart, mesenterium and skin may be involved. Typical histopathology is lymphoplasmacytic infiltration abundant in IgG4-positive plasma cells, storiform-type fibrosis, and obliterative phlebitis. Elevated serum IgG4 concentration supports the diagnosis. Characteristic imaging features such as a capsule -like rim surrounding the pancreatic lesions is highly specific to type 1 AIP. 18F-Iluorodeoxyglucose positron emission tomography/computed tomography enables mapping the sites of inflammation, permits evaluation of the extent of the disease, helps in guiding biopsy decision, and may be used in monitoring response to treatment. Glucocorticoids alone or in combination with B -cell depletion with rituximab induces prompt clinical response to IgG4-RD. This article reviews the current understanding, different clinical manifestations, and approaches to diagnosis and treatment of IgG4-RD. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available